GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004114 describes the enzymatic activity that hydrolyzes a nucleoside 3',5'-cyclic phosphate to the corresponding nucleoside 5'-phosphate.
• This activity is widely distributed across human tissues, with DEAE-cellulose chromatography revealing distinct phosphodiesterase forms in platelets, brain, and other organs.
• Calcium-dependent regulation is a hallmark of certain 3',5'-cyclic-nucleotide phosphodiesterases, and potassium ions can inhibit basal activity at physiological concentrations.
• The enzyme exists in low-Km and high-Km forms in human platelets, indicating multiple kinetic classes with different substrate affinities.
• Bacterial homologs such as cpdP from Vibrio fischeri demonstrate that 3',5'-cyclic-nucleotide phosphodiesterase activity is evolutionarily conserved beyond mammals.
• Altered phosphodiesterase activity has been observed in pathological states, including elevated serum activity in phaeochromocytoma.
Description
3',5'-cyclic-nucleotide phosphodiesterase activity (GO:0004114) is a molecular function that catalyzes the hydrolysis of a nucleoside 3',5'-cyclic phosphate to a nucleoside 5'-phosphate. This reaction is central to cyclic nucleotide metabolism because it terminates the signaling actions of molecules such as cyclic AMP and cyclic GMP. The activity was first characterized biochemically in mammalian tissues, where DEAE-cellulose chromatography resolved multiple peaks of enzyme activity from human platelets, brain, and other sources. These early studies established that 3',5'-cyclic-nucleotide phosphodiesterase activity is not a single entity but a family of enzymes with distinct kinetic properties, including low-Km and high-Km forms. The enzyme has also been detected in bovine pituitary gland and in the marine bacterium Vibrio fischeri, underscoring its broad phylogenetic distribution. For researchers, GO:0004114 provides a precise functional annotation for genes and proteins that regulate cyclic nucleotide levels, making it a key term in studies of signal transduction, neurobiology, and endocrine disease.
3',5'-cyclic-nucleotide phosphodiesterase activity At A Glance
| GO ID | GO:0004114 |
|---|---|
| GO term | 3',5'-cyclic-nucleotide phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | cyclic nucleotide phosphodiesterase activity; cyclic AMP phosphodiesterase activity; PDE; 3',5'-cyclic-nucleotide 5'-nucleotidohydrolase activity |
| Major function | Hydrolysis of a nucleoside 3',5'-cyclic phosphate to a nucleoside 5'-phosphate |
| Reaction | nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate |
| Subcellular context | Cytoplasmic and membrane-associated forms have been described in mammalian tissues |
| Regulation | Calcium-dependent stimulation and inhibition by physiological potassium ions |
| Kinetic classes | Low-Km and high-Km forms identified in human platelets |
What Is GO:0004114?
According to the Gene Ontology, GO:0004114 (3',5'-cyclic-nucleotide phosphodiesterase activity) is defined as the catalysis of the reaction: a nucleoside 3',5'-cyclic phosphate + H2O = a nucleoside 5'-phosphate. In other words, this activity breaks the cyclic phosphate bond of a nucleoside 3',5'-cyclic monophosphate, releasing the corresponding nucleoside 5'-monophosphate. The term is synonymous with cyclic nucleotide phosphodiesterase activity, cyclic AMP phosphodiesterase activity, and PDE, among other names. It is a molecular_function term, meaning it describes what a gene product does at the biochemical level rather than where it acts or what process it participates in.
Why Is 3',5'-cyclic-nucleotide phosphodiesterase activity Important in Cell Biology?
3',5'-cyclic-nucleotide phosphodiesterase activity is essential for terminating cyclic nucleotide signaling, and its dysregulation has been linked to endocrine and neurological disorders. The enzyme was found at high activity in sera of patients with phaeochromocytoma, suggesting a potential biomarker role. In the brain, calcium-dependent forms are stimulated by lysophosphatidylcholine and modulated by potassium ions, indicating tight control of cyclic nucleotide levels in neural tissue. Because the activity is conserved from bacteria to humans, it also serves as a model for studying enzyme evolution and cyclic nucleotide metabolism.
• Terminates cyclic AMP and cyclic GMP signaling, controlling downstream kinase activity.
• Provides a biochemical marker in endocrine tumors such as phaeochromocytoma.
• Exhibits calcium-dependent regulation, linking it to calcium signaling pathways.
• Exists as multiple kinetic forms (low-Km and high-Km) that may serve distinct physiological roles.
• Is present in human platelets, where it regulates platelet reactivity.
• Is found in bovine pituitary gland, suggesting a role in hormone secretion.
• Is conserved in bacteria such as Vibrio fischeri, enabling comparative studies.
• Is stimulated by lysophosphatidylcholine in brain cytoplasm, indicating lipid regulation.
• Can be inhibited by physiological potassium ions, a unique regulatory feature.
• Serves as a target for pharmacological modulation in cardiovascular and neurological research.
What Happens During 3',5'-cyclic-nucleotide phosphodiesterase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs a cyclic nucleotide molecule and holds it in place.
The reaction begins when the enzyme binds a nucleoside 3',5'-cyclic phosphate, such as cyclic AMP or cyclic GMP. Human platelet phosphodiesterases have been resolved into low-Km and high-Km forms, indicating that substrate affinity varies among enzyme variants. The binding step is influenced by ions; physiological levels of potassium ions inhibit basal activity, suggesting that the ionic environment modulates substrate interaction.
Catalytic hydrolysis
In simple terms: Water is used to break the ring, converting the cyclic nucleotide into a linear form.
The enzyme catalyzes the hydrolysis of the cyclic phosphate bond, yielding a nucleoside 5'-phosphate. This activity has been measured in various human tissues by DEAE-cellulose chromatography, confirming the presence of multiple catalytic species. The reaction is dependent on the presence of the cyclic nucleotide substrate and is a key step in terminating cyclic nucleotide signaling.
Calcium-dependent activation
In simple terms: Calcium ions help switch the enzyme on by changing its shape.
Certain 3',5'-cyclic-nucleotide phosphodiesterases are activated by calcium. The protein activator undergoes a conformational change, becoming more helical upon calcium binding, which stimulates the enzyme. This calcium-dependent regulation is a hallmark of specific phosphodiesterase forms in the brain and other tissues.
Lipid stimulation
In simple terms: Certain fat-like molecules can boost the enzyme's activity.
Lysophosphatidylcholine stimulates the bovine brain cytoplasmic enzyme, revealing a lipid-mediated regulatory mechanism. This suggests that membrane-derived lipids can modulate phosphodiesterase activity in vivo, adding another layer of control beyond calcium and ions.
Ion sensitivity
In simple terms: The enzyme's activity can be turned down by potassium ions.
Physiological levels of potassium ions inhibit basal activity of the calcium-dependent phosphodiesterase, indicating that the enzyme integrates ionic signals. This inhibition may prevent excessive cyclic nucleotide breakdown under resting conditions, allowing for dynamic regulation.
Key Genes Involved in GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity
The following genes and proteins have been experimentally associated with 3',5'-cyclic-nucleotide phosphodiesterase activity or its regulation in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE1 | Calcium/calmodulin-dependent phosphodiesterase | Studied for calcium-dependent regulation in brain |
| PDE2 | cGMP-stimulated phosphodiesterase | Potential role in cyclic nucleotide cross-talk |
| PDE3 | cGMP-inhibited phosphodiesterase | Expressed in platelets and cardiovascular tissues |
| PDE4 | cAMP-specific phosphodiesterase | Major regulator of cAMP in immune and brain cells |
| PDE5 | cGMP-specific phosphodiesterase | Target of inhibitors in erectile dysfunction |
| PDE6 | Photoreceptor phosphodiesterase | Critical for visual signal transduction |
| PDE7 | High-affinity cAMP phosphodiesterase | Studied in T-cell activation |
| PDE8 | cAMP-specific phosphodiesterase | Role in hormone secretion |
| PDE9 | cGMP-specific phosphodiesterase | Potential target in cognition |
| PDE10 | Dual cAMP/cGMP phosphodiesterase | Expressed in brain and testes |
| PDE11 | Dual cAMP/cGMP phosphodiesterase | Found in prostate and skeletal muscle |
| cpdP | Periplasmic phosphodiesterase in Vibrio fischeri | Bacterial model for enzyme evolution |
| CALM1 | Calmodulin, activator of PDE1 | Calcium-dependent activation via conformational change |
| PRKACA | cAMP-dependent protein kinase | Downstream effector of cyclic AMP signaling |
| PRKG1 | cGMP-dependent protein kinase | Downstream effector of cyclic GMP signaling |
| ADCY1 | Adenylyl cyclase, produces cAMP | Opposing enzyme to phosphodiesterase |
| GUCY1A1 | Guanylyl cyclase, produces cGMP | Opposing enzyme to phosphodiesterase |
How Is 3',5'-cyclic-nucleotide phosphodiesterase activity Regulated?
3',5'-cyclic-nucleotide phosphodiesterase activity is regulated by multiple mechanisms. Calcium ions activate specific forms by inducing a conformational change in the protein activator, increasing its helical content. Physiological concentrations of potassium ions inhibit basal activity, providing a feedback mechanism. Lysophosphatidylcholine stimulates the bovine brain cytoplasmic enzyme, indicating lipid-mediated regulation. Additionally, the existence of low-Km and high-Km forms in human platelets suggests that substrate affinity and expression levels are regulated to meet cellular demands.
3',5'-cyclic-nucleotide phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE1 | Neurological disorders, calcium signaling | Knockout mice or neuronal cell lines |
| PDE3 | Cardiovascular disease, platelet function | Platelet-specific knockout or overexpression |
| PDE4 | Inflammation, depression | Knockout mice or immune cell lines |
| PDE5 | Erectile dysfunction, pulmonary hypertension | Knock-in of point mutations |
| cpdP | Bacterial cyclic nucleotide metabolism | Vibrio fischeri knockout |
Phaeochromocytoma
High activity of cyclic 3',5'-nucleotide phosphodiesterase has been reported in sera of patients with phaeochromocytoma, suggesting that the enzyme may serve as a biochemical marker for this endocrine tumor. The elevated activity could reflect tumor-derived secretion or systemic response to catecholamine excess.
Neurological and psychiatric disorders
Calcium-dependent phosphodiesterases are enriched in the brain, where they regulate cyclic nucleotide levels critical for neuronal signaling. Dysregulation of these enzymes has been implicated in conditions such as depression and cognitive disorders, although direct evidence from the cited literature is limited to biochemical characterization.
Cardiovascular and platelet disorders
Human platelets contain both low-Km and high-Km phosphodiesterases, which control cAMP and cGMP levels and influence platelet aggregation. Altered phosphodiesterase activity may contribute to thrombotic or bleeding tendencies, making these enzymes potential targets for antiplatelet therapy.
From 3',5'-cyclic-nucleotide phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDE1 affect calcium-dependent cAMP hydrolysis? | PDE1 knockout cell line |
| How does a point mutation in the catalytic domain alter Km? | Point-mutation knock-in |
| Can a tagged PDE4 be used to track subcellular localization? | Tagged knock-in |
| Does overexpression of PDE3 reduce platelet aggregation? | Overexpression cell model |
| Which genes regulate phosphodiesterase activity in brain? | CRISPR library screening |
| What is the role of cpdP in Vibrio fischeri? | Bacterial knockout |
How to Study the 3',5'-cyclic-nucleotide phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive enzyme assay | Conversion of cyclic nucleotide to 5'-nucleotide | Quantifying phosphodiesterase activity in tissue extracts |
| DEAE-cellulose chromatography | Separation of enzyme isoforms | Resolving low-Km and high-Km forms |
| Circular dichroism | Protein conformational changes | Calcium-induced helical change in activator |
| Kinetic analysis | Km and Vmax | Comparing substrate affinity of isoforms |
| Serum activity assay | Enzyme activity in blood | Biomarker detection in phaeochromocytoma |
| Bacterial genetics | Gene knockout and activity | Characterizing cpdP in Vibrio fischeri |
| Lysophosphatidylcholine stimulation assay | Lipid-dependent activation | Studying brain cytoplasmic enzyme |
| Potassium inhibition assay | Ion sensitivity | Assessing physiological regulation |
Biochemical enzyme assays
Classical phosphodiesterase assays measure the conversion of cyclic nucleotides to 5'-nucleotides using radioactive or fluorescent substrates. DEAE-cellulose chromatography has been used to resolve multiple forms from human tissues. These assays remain the gold standard for quantifying GO:0004114 activity.
Kinetic characterization
Determination of Km and Vmax values distinguishes low-Km from high-Km forms, as demonstrated in human platelets. Such kinetic studies are essential for understanding substrate specificity and regulation.
Calcium-binding and conformational studies
Circular dichroism and other biophysical methods have shown that calcium binding increases the helical content of the protein activator, providing mechanistic insight into regulation.
Tissue distribution analysis
DEAE-cellulose chromatography of various human tissues has revealed tissue-specific patterns of phosphodiesterase activity, informing studies of organ-specific cyclic nucleotide signaling.
How CRISPR Can Be Used to Study GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity
Knockout
CRISPR knockout of phosphodiesterase genes can abolish specific enzyme activities, allowing researchers to determine which isoform is responsible for cyclic nucleotide hydrolysis in a given cell type. For example, knocking out PDE4 in immune cells would reveal its contribution to cAMP regulation.
Point Mutation
Introducing point mutations in the catalytic domain can alter Km or Vmax, enabling structure-function studies. Such models are valuable for understanding how specific residues contribute to substrate binding and catalysis.
Knock-in
Knock-in of tagged versions of phosphodiesterase genes allows real-time tracking of enzyme localization and dynamics. This approach can reveal whether the enzyme translocates upon calcium or lipid stimulation.
Overexpression
Overexpression of a phosphodiesterase gene can reduce intracellular cyclic nucleotide levels, mimicking a state of enhanced degradation. This is useful for studying downstream effects on signaling pathways and cellular phenotypes.
How EDITGENE Supports 3',5'-cyclic-nucleotide phosphodiesterase activity Research
Researchers studying 3',5'-cyclic-nucleotide phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in cyclic nucleotide hydrolysis, how mutations affect enzyme kinetics, and where the protein acts within the cell. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for 3',5'-cyclic-nucleotide phosphodiesterase activity research.
Frequently Asked Questions About 3',5'-cyclic-nucleotide phosphodiesterase activity
What is 3',5'-cyclic-nucleotide phosphodiesterase activity?
It is the enzymatic activity that hydrolyzes a nucleoside 3',5'-cyclic phosphate to a nucleoside 5'-phosphate, as defined by GO:0004114.
What genes are involved in 3',5'-cyclic-nucleotide phosphodiesterase activity?
Genes encoding phosphodiesterases such as PDE1, PDE3, PDE4, and PDE5, as well as regulatory proteins like calmodulin, are involved.
How is 3',5'-cyclic-nucleotide phosphodiesterase activity regulated?
It is regulated by calcium, potassium ions, and lipids such as lysophosphatidylcholine.
What diseases are associated with 3',5'-cyclic-nucleotide phosphodiesterase activity?
Phaeochromocytoma, neurological disorders, and platelet-related conditions have been linked to altered activity.
What are the substrates of 3',5'-cyclic-nucleotide phosphodiesterase?
Cyclic AMP and cyclic GMP are the primary substrates, but other nucleoside 3',5'-cyclic phosphates can also be hydrolyzed.
How can I measure 3',5'-cyclic-nucleotide phosphodiesterase activity?
Biochemical assays using radioactive or fluorescent substrates, often combined with DEAE-cellulose chromatography, are standard methods.
What is the difference between low-Km and high-Km phosphodiesterase?
Low-Km forms have high affinity for substrate and are active at low concentrations, while high-Km forms require higher substrate levels, as shown in human platelets.
Is 3',5'-cyclic-nucleotide phosphodiesterase activity conserved in bacteria?
Yes, a periplasmic phosphodiesterase gene, cpdP, has been characterized in Vibrio fischeri.
How does calcium affect 3',5'-cyclic-nucleotide phosphodiesterase activity?
Calcium binding to the protein activator induces a conformational change that stimulates enzyme activity.
Can CRISPR be used to study 3',5'-cyclic-nucleotide phosphodiesterase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting the function of phosphodiesterase genes.
Conclusion
3',5'-cyclic-nucleotide phosphodiesterase activity (GO:0004114) is a fundamental enzymatic function that controls cyclic nucleotide signaling across diverse organisms. Its biochemical properties, including calcium dependence, ion sensitivity, and multiple kinetic forms, have been well documented in human tissues and model systems. Dysregulation of this activity is associated with diseases such as phaeochromocytoma, highlighting its clinical relevance. Continued research using CRISPR-based models and biochemical assays will further elucidate its roles in health and disease.
References
- 1. Nakai A et al.. 1986. High activity of cyclic 3',5'-nucleotide phosphodiesterase in sera of patient with phaeochromocytoma.. Clin Endocrinol (Oxf) 24(4):409-14 PMID: 3017609
- 2. Davis CW et al.. 1978. Calcium-dependent 3':5'-cyclic nucleotide phosphodiesterase. Inhibition of basal activity at physiological levels of potassium ions.. J Biol Chem 253(24):8683-6 PMID: 214428
- 3. Hidaka H et al.. 1977. Cyclic 3':5'-nucleotide phosphodiesterase determined in various human tissues by DEAE-cellulose chromatography.. Biochim Biophys Acta 484(2):398-407 PMID: 199262
- 4. Hidaka H et al.. 1976. Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase.. Biochim Biophys Acta 429(2):485-97 PMID: 177073
- 5. Nagasaka A et al.. 1983. 3':5'-cyclic-nucleotide phosphodiesterase in the bovine pituitary gland.. Biochim Biophys Acta 755(3):481-7 PMID: 6297613
- 6. Dunlap PV et al.. 1993. Characterization of a periplasmic 3':5'-cyclic nucleotide phosphodiesterase gene, cpdP, from the marine symbiotic bacterium Vibrio fischeri.. J Bacteriol 175(15):4615-24 PMID: 8393003
- 7. Pichard AL et al.. 1977. Cyclic 3':5'-nucleotide phosphodiesterase. Stimulation of bovine brain cytoplasmic enzyme by lysophosphatidylcholine.. J Biol Chem 252(14):4872-5 PMID: 194898
- 8. Liu YP et al.. 1976. Cyclic 3':5'-nucleotide phosphodiesterase. Ca2+ confers more helical conformation to the protein activator.. J Biol Chem 251(14):4193-8 PMID: 180019
